secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2022-10-18T23:59:59+00:00
Accession:  0001789769-22-000087
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio doses first patient with ITIL-306 CoStAR-TIL in Phase 1 NSCLC trial
------------------------------------------------------------------------------

- First patient dosed in Phase 1 study of ITIL-306, a CoStAR-engineered TIL therapy targeting FRα in non-small cell lung cancer.
- ITIL-306 designed to enhance TIL activity in tumor microenvironment and eliminate need for high-dose IL-2.
- Initial clinical data from dose escalation cohorts expected in 2023.
- Phase 1 open-label multicenter study also includes ovarian and renal cell carcinoma patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976922000087/0001789769-22-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976922000087/til-20221018.htm
  HTML page:      https://secwatch.observer/filing/0001789769-22-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer